OTONOMY INC (OTIC) Stock Price, Forecast & Analysis
NASDAQ:OTIC • US68906L1052
OTIC Key Statistics, Chart & Performance
The current stock price of OTIC is 0.077 USD. In the past month the price decreased by -29.87%. In the past year, price decreased by -96.65%.
OTIC Technical Analysis
OTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTIC. OTIC may be in some trouble as it scores bad on both profitability and health.
OTIC Financial Highlights
Over the last trailing twelve months OTIC reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 4.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |
OTIC Forecast & Estimates
9 analysts have analysed OTIC and the average price target is 9.18 USD. This implies a price increase of 11822.08% is expected in the next year compared to the current price of 0.077.
For the next year, analysts expect an EPS growth of 3.04% and a revenue growth -100% for OTIC
OTIC Ownership
OTIC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OTIC
Company Profile
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Company Info
OTONOMY INC
5626 Oberlin Drive, Suite 100
San Diego CALIFORNIA 92121 US
CEO: David A. Weber
Employees: 51
Phone: 18587687823.0
OTONOMY INC / OTIC FAQ
What does OTIC do?
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Can you provide the latest stock price for OTONOMY INC?
The current stock price of OTIC is 0.077 USD. The price decreased by -11.19% in the last trading session.
Does OTIC stock pay dividends?
OTIC does not pay a dividend.
What is the ChartMill technical and fundamental rating of OTIC stock?
OTIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for OTONOMY INC?
OTONOMY INC (OTIC) has a market capitalization of 4.40M USD. This makes OTIC a Nano Cap stock.
What is the next earnings date for OTIC stock?
OTONOMY INC (OTIC) will report earnings on 2023-02-27.